2021-2022 Medicine-Hematology Oncology Grand Rounds, 22D12

Occurs weekly every Friday starting on 8/6/2021 at 8:00 AM
Friday, August 6, 2021, 8:00 AM - 9:15 AM, Zoom Videoconference, Oklahoma City, OK


The hematology oncology field is very diverse which includes all aspects of management of blood disorders and cancer diagnostics and therapeutics. Grand rounds is a weekly one hour presentation incorporating interactive learning environment. Usually the presenter is an external speaker visiting from another institution or another department. The focus of the grands rounds is to update the audience about the advances in the field and discuss topics relevant to hematology/oncology which can serve as a platform to enhance knowledge and better patient care in addition trigger ideas for research. Sessions are usually followed by discussion toward the end with time for questions. 

1. Apply the most current evidence-based medicine and literature to their practice
2. Apply specific use of diagnostic procedures and medications

Accreditation Statement: The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a mximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Conflict Resolution Statement: The University of Oklahoma college of Medicine, Office of Continuing Professional Development has reviewed this activity's speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

Nondiscrimination Statement:  The University of Oklahoma, in compliance with all applicable federal and state laws and regulations does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. this includes, but is not limited to: admissions, employment, financial aid, and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, [email protected], or visit www.ou.edu/eoo.

The University of Oklahoma is an Equal Opportunity Institution. www.ou.edu/eoo

Accommodation Statement: Is available by calling 271-4022 ext. 48342.

Disclaimer Statement: Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma ("OU") nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negilgence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty and Presenter Disclosure: It is the policy of the University of Oklahoma College of Medicine that the faculty and preenters disclose real or apparent conflicts of interest relating to the topics of this educational acitivty, and also discloses discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).

AMA PRA Category 1 Credits™ (1.25 hours), Non-Physician Attendance (1.25 hours)

Planning Committe Members

Course Director: Mohamad Khawandanah, MD
Course Contact: Robin Vinson
Raid Aljumaily, MD
Adam Asch, MD
JK Feisal, MD

Date	Empty Column	Title
6/3/2022 8:00:00 AM	The Conundrum of Thrombophilia Testing: How Much is Too Much and How Much is Too Little?, 22D12 - 6/3/2022 6/3/2022 8:00:00 AM 6/3/2022 9:15:00 AM 11 Zoom Videoconference False MM/DD/YYYY	The Conundrum of Thrombophilia Testing: How Much is Too Much and How Much is Too Little?, 22D12 - 6/3/2022 The hematology oncology field is very diverse which includes all aspects of management of blood disorders and cancer diagnostics and therapeutics. Grand rounds is a weekly one hour presentation incorporating interactive learning environment. Usually the presenter is an external speaker visiting from another institution or another department. The focus of the grands rounds is to update the audience about the advances in the field and discuss topics relevant to hematology/oncology which can serve as a platform to enhance knowledge and better patient care in addition trigger ideas for research. Sessions are usually followed by discussion toward the end with time for questions.  Professional Practice Gaps:  1) Thrombophilia testing is routinely performed on patients with thrombotic events and women with pregnancy loss, however we are uncertain that the results do or should cause providers to change acute management.  There is also confusion about best timing for testing and what medications interfere with testing. 2) Many adults who are identified with a mild thrombophilia are placed on life-long anticoagulation.  We do not clearly understand the risk of recurrent thrombotic events based on thrombophilia identified and what is the appropriate duration of therapy. 3) When adults are identified with a thrombophilia, it is often recommended that family members are tested, even very young children.  This is a very debatable practice. Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: 1) Recognize the pathophysiology of most of the inherited and acquired thrombophilias. 2) Discuss the appropriate testing to conduct and in which situations and comorbid conditions to perform testing. 3) Relate the importance of carefully recommending family testing for thrombophilias. Download Announcement Location: Zoom Videoconference Specialties: Hematology, Oncology

Acknowledgement of Commercial and In-Kind Support:
This activity received no commercial or in-kind support.